FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017545176> ?p ?o ?g. }

• W2017545176 endingPage "e28" @default.
• W2017545176 startingPage "e27" @default.
• W2017545176 abstract "Positron emission tomography (PET) with [(18)F]fluorodeoxyglucose is increasingly used in early assessment of tumor response in non–small-cell lung cancer (NSCLC).1Takahashi R Hirata H Tachibana I et al.Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung.Clin Cancer Res. 2012; 18: 220-228Crossref PubMed Scopus (76) Google Scholar Circulating tumor cells (CTCs) are detectable in patients with NSCLC and might provide early indication of response to therapy.2Krebs MG Sloane R Priest L et al.Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer.J Clin Oncol. 2011; 29: 1556-1563Crossref PubMed Scopus (712) Google Scholar This report describes the role of PET and CTCs in monitoring the response to gefitinib in a patient affected by metastatic lung adenocarcinoma harboring an activating epidermal growth factor receptor (EGFR) mutation and with an extremely poor performance status. On November 2010, a 41-year-old man, a former light smoker, was admitted to our institution for a right lung nodule with pleural effusion, pericardial effusion, disseminated intravascular coagulation, and renal and hepatic failure. The Eastern Cooperative Oncology Group performance status was 4. PET scan demonstrated tracer accumulation in the right lung, pleural, supraclavicular and mediastinic lymph nodes, bone and liver (Fig. 1A). The patient underwent pericardial drainage and started therapy with steroids, diuretics, low–molecular-weight heparin, antithrombin III, and fresh frozen plasma. Cytologic evaluation of pericardial effusion demonstrated a lung adenocarcinoma. A single slide containing 20 stained tumor cells was available for EGFR mutational analysis. By using highly sensitive fragment analysis and polymerase chain reaction/sequencing techniques, it was possible to demonstrate in exon 19 of the EGFR gene a c.2235–2249 deletion, producing the aminoacidic deletion p.E746-A750. Finally, analysis of 7.5 mL of peripheral blood sample with the CellSearch system (Veridex, Raritan, NJ) revealed the presence of 32 CTCs, in which the same EGFR deletion identified in the primary tumor was detected. On December 15, we started therapy with gefitinib 250 mg/day, with a rapid and dramatic improvement of clinical conditions. After 2 weeks of treatment, the CTC count was 0. The PET scan after 3 months of therapy showed only a minimal tracer accumulation at the basis of the right lung (standardized uptake value 3.3) (Fig. 1B), and became negative after 7 months of therapy (Fig. 1C). Response to gefitinib was maintained for 11 months, until November 2011, when a total body PET/computed tomography scan showed a liver progression of disease, whereas CTC count was still negative. Six randomized clinical trials demonstrated the efficacy of gefitinib and erlotinib in patients with EGFR-mutation–positive NSCLC and good performance status (Eastern Cooperative Oncology Group 0–1).3Costanzo R Piccirillo MC Sandomenico C et al.Gefitinib in non small cell lung cancer.J Biomed Biotechnol. 2011; 2011: 815269Crossref PubMed Scopus (29) Google Scholar Some reports showed that Asian patients with advanced NSCLC and poor performance status can be responsive to gefitinib.4Inoue A Kobayashi K Usui K North East Japan Gefitinib Study Group et al.First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.J Clin Oncol. 2009; 27: 1394-1400Crossref PubMed Scopus (444) Google Scholar This case confirms the possibility of successful treatment in a patient with an EGFR mutation and a poor performance status. More importantly, our findings highlight the importance of applying highly sensitive testing methods to allow the identification of EGFR mutations even in samples containing a low number of tumor cells, especially in patients who present clinical characteristics associated with a high incidence of EGFR mutations. In this regard, the assessment of EGFR mutations in CTCs might represent an alternative approach in patients for whom samples from the primary tumor are not available.5Maheswaran S Sequist LV Nagrath S et al.Detection of mutations in EGFR in circulating lung-cancer cells.N Engl J Med. 2008; 359: 366-377Crossref PubMed Scopus (1473) Google Scholar Finally, this study also suggests that both PET analysis and CTC count might have a relevant role in monitoring the response to molecular-targeted agents." @default.
• W2017545176 created "2016-06-24" @default.
• W2017545176 creator A5002665417 @default.
• W2017545176 creator A5003014678 @default.
• W2017545176 creator A5009029772 @default.
• W2017545176 creator A5020456545 @default.
• W2017545176 creator A5023150524 @default.
• W2017545176 creator A5031019737 @default.
• W2017545176 creator A5032887264 @default.
• W2017545176 creator A5051933262 @default.
• W2017545176 creator A5062023516 @default.
• W2017545176 creator A5067154545 @default.
• W2017545176 creator A5070025173 @default.
• W2017545176 creator A5091532757 @default.
• W2017545176 date "2012-11-01" @default.
• W2017545176 modified "2023-10-18" @default.
• W2017545176 title "Positron Emission Tomography and Circulating Tumor Cells to Monitor a Dramatic Response to Gefitinib" @default.
• W2017545176 cites W2019615042 @default.
• W2017545176 cites W2108816382 @default.
• W2017545176 cites W2111191667 @default.
• W2017545176 cites W2129224219 @default.
• W2017545176 cites W2139799027 @default.
• W2017545176 doi "https://doi.org/10.1097/jto.0b013e3182653da2" @default.
• W2017545176 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23070247" @default.
• W2017545176 hasPublicationYear "2012" @default.
• W2017545176 type Work @default.
• W2017545176 sameAs 2017545176 @default.
• W2017545176 citedByCount "8" @default.
• W2017545176 countsByYear W20175451762013 @default.
• W2017545176 countsByYear W20175451762015 @default.
• W2017545176 countsByYear W20175451762016 @default.
• W2017545176 countsByYear W20175451762017 @default.
• W2017545176 countsByYear W20175451762019 @default.
• W2017545176 countsByYear W20175451762021 @default.
• W2017545176 crossrefType "journal-article" @default.
• W2017545176 hasAuthorship W2017545176A5002665417 @default.
• W2017545176 hasAuthorship W2017545176A5003014678 @default.
• W2017545176 hasAuthorship W2017545176A5009029772 @default.
• W2017545176 hasAuthorship W2017545176A5020456545 @default.
• W2017545176 hasAuthorship W2017545176A5023150524 @default.
• W2017545176 hasAuthorship W2017545176A5031019737 @default.
• W2017545176 hasAuthorship W2017545176A5032887264 @default.
• W2017545176 hasAuthorship W2017545176A5051933262 @default.
• W2017545176 hasAuthorship W2017545176A5062023516 @default.
• W2017545176 hasAuthorship W2017545176A5067154545 @default.
• W2017545176 hasAuthorship W2017545176A5070025173 @default.
• W2017545176 hasAuthorship W2017545176A5091532757 @default.
• W2017545176 hasBestOaLocation W20175451761 @default.
• W2017545176 hasConcept C121608353 @default.
• W2017545176 hasConcept C126322002 @default.
• W2017545176 hasConcept C126838900 @default.
• W2017545176 hasConcept C142724271 @default.
• W2017545176 hasConcept C143998085 @default.
• W2017545176 hasConcept C2775842073 @default.
• W2017545176 hasConcept C2776256026 @default.
• W2017545176 hasConcept C2778087573 @default.
• W2017545176 hasConcept C2779438470 @default.
• W2017545176 hasConcept C2779634585 @default.
• W2017545176 hasConcept C2780580887 @default.
• W2017545176 hasConcept C2781182431 @default.
• W2017545176 hasConcept C71924100 @default.
• W2017545176 hasConceptScore W2017545176C121608353 @default.
• W2017545176 hasConceptScore W2017545176C126322002 @default.
• W2017545176 hasConceptScore W2017545176C126838900 @default.
• W2017545176 hasConceptScore W2017545176C142724271 @default.
• W2017545176 hasConceptScore W2017545176C143998085 @default.
• W2017545176 hasConceptScore W2017545176C2775842073 @default.
• W2017545176 hasConceptScore W2017545176C2776256026 @default.
• W2017545176 hasConceptScore W2017545176C2778087573 @default.
• W2017545176 hasConceptScore W2017545176C2779438470 @default.
• W2017545176 hasConceptScore W2017545176C2779634585 @default.
• W2017545176 hasConceptScore W2017545176C2780580887 @default.
• W2017545176 hasConceptScore W2017545176C2781182431 @default.
• W2017545176 hasConceptScore W2017545176C71924100 @default.
• W2017545176 hasIssue "11" @default.
• W2017545176 hasLocation W20175451761 @default.
• W2017545176 hasLocation W20175451762 @default.
• W2017545176 hasOpenAccess W2017545176 @default.
• W2017545176 hasPrimaryLocation W20175451761 @default.
• W2017545176 hasRelatedWork W1803443763 @default.
• W2017545176 hasRelatedWork W1976268611 @default.
• W2017545176 hasRelatedWork W2050376166 @default.
• W2017545176 hasRelatedWork W2053686268 @default.
• W2017545176 hasRelatedWork W2081740550 @default.
• W2017545176 hasRelatedWork W2131782945 @default.
• W2017545176 hasRelatedWork W2186047679 @default.
• W2017545176 hasRelatedWork W2540520719 @default.
• W2017545176 hasRelatedWork W2888534976 @default.
• W2017545176 hasRelatedWork W2978946191 @default.
• W2017545176 hasVolume "7" @default.
• W2017545176 isParatext "false" @default.
• W2017545176 isRetracted "false" @default.
• W2017545176 magId "2017545176" @default.
• W2017545176 workType "article" @default.